Can Minimal Change Disease Cause Anemia?
Yes, minimal change disease (MCD) can cause anemia, though it is uncommon and typically occurs in specific clinical contexts—most notably when MCD presents with acute kidney injury (AKI) or through mechanisms related to nephrotic syndrome itself.
Understanding the Association
While anemia is not a typical feature of uncomplicated MCD, several documented mechanisms explain when and how it occurs:
Direct Disease-Related Mechanisms
Acute Kidney Injury with MCD is the most clinically significant scenario where severe anemia can develop. When MCD presents with AKI (occurring in approximately 31% of adult MCD cases 1), patients may develop profound anemia requiring transfusion and erythropoietin therapy 2. This represents a unique presentation where the combination of severe proteinuria, AKI, and anemia occurs together—a triad not typically seen in standard MCD presentations.
Erythropoietin dysregulation in nephrotic syndrome can contribute to anemia through two pathways 3:
- Urinary losses of erythropoietin due to heavy proteinuria
- Altered biosynthesis preventing the normal exponential increase in erythropoietin production that should occur in response to anemia
- This mechanism resolves when the nephrotic syndrome is treated, with simultaneous improvement of both conditions
Hemodilution Effects
Plasma volume expansion from severe hypoalbuminemia can create a dilutional anemia 3. This pseudoanemia shows significant correlation between hemoglobin concentration and serum total protein levels, improving as the nephrotic syndrome resolves with steroid therapy.
Rare Concurrent Presentations
Aplastic anemia has been reported concurrently with MCD 4, though this represents a separate immunological process rather than a direct causative relationship. Both conditions may share common T-lymphocyte activation pathways.
Clinical Recognition and Workup
When evaluating a patient with MCD who presents with anemia, consider:
Key laboratory assessment:
- Complete blood count with indices (MCV, RDW)
- Reticulocyte count to assess bone marrow response
- Serum ferritin and transferrin saturation to exclude iron deficiency 5
- Renal function (creatinine, eGFR) to identify AKI
- Serum albumin and 24-hour urine protein to quantify nephrotic syndrome severity
Red flags requiring hematology consultation:
- Abnormalities in two or more cell lines (suggesting bone marrow dysfunction) 5
- Severe anemia disproportionate to the degree of renal dysfunction
- Failure to respond to treatment of the underlying MCD
Management Approach
For MCD-associated anemia with AKI 2:
- Initiate corticosteroid therapy for the underlying MCD
- Consider early erythropoietin therapy (may facilitate renal recovery)
- Provide transfusion support for symptomatic anemia or hemoglobin <7-8 g/dL
- Monitor closely for resolution as nephrotic syndrome improves
For dilutional anemia in nephrotic syndrome 3:
- Treat the underlying MCD with appropriate immunosuppression
- Anemia typically resolves as proteinuria decreases and albumin normalizes
- Avoid unnecessary iron supplementation if true iron deficiency is not present
Important Clinical Pitfalls
Do not assume anemia is always unrelated to MCD. While uncommon, the association exists and requires recognition, particularly in the setting of AKI 2.
Do not delay steroid therapy when MCD is confirmed by biopsy, even in the presence of severe anemia—treatment of the underlying disease often resolves the anemia 3.
Do not overlook alternative causes. MCD patients can have concurrent iron deficiency, chronic disease anemia, or other hematologic conditions that require separate evaluation 5.
The prognosis for anemia associated with MCD is generally excellent when the underlying nephrotic syndrome responds to treatment, with complete resolution of both conditions typically occurring within 4-6 weeks of initiating appropriate therapy 2, 3.